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TherapyThe anti-inflammatory agents glucocorticoids (GC) are the only available treatment for Duchennemuscular dys-
trophy (DMD). However, long-term GC treatment causes muscle atrophy and wasting. Thus, targeting specific
mediator of inflammatory response may be more specific, more efficacious, and with fewer side effects. The
pro-inflammatory cytokine interleukin (IL) 6 is overproduced in patients with DMD and in the muscle of mdx,
the animalmodel for humanDMD.We tested the ability of inhibition of IL6 activity, using an interleukin-6 recep-
tor (Il6r) neutralizing antibody, to ameliorate the dystrophic phenotype. Blockade of endogenous Il6r conferred
on dystrophicmuscle resistance to degeneration and alleviated bothmorphological and functional consequences
of the primary genetic defect. Pharmacological inhibition of IL6 activity leaded to changes in the dystrophicmus-
cle environment, favoring anti-inflammatory responses and improvement in muscle repair. This resulted in a
functional homeostatic maintenance of dystrophic muscle.
These data provide an alternative pharmacological strategy for treatment of DMD and circumvent the major
problems associated with conventional therapy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Duchennemuscular dystrophy (DMD) is anX-linked genetic disease
caused bymutations in the dystrophin gene that result in dysfunctional
or absent dystrophin protein. The absence of dystrophin causes instabil-
ity of the dystrophin–glycoprotein complex (DGC) with alterations in
intracellular signaling leading to an imbalance between protein synthe-
sis and protein degradation, with subsequent necrosis and fibrosis
(Glass, 2007). The mdx mouse strain, with a point mutation within its
dystrophin gene, has served as the animal model for human DMD
(Carnwath and Shotton, 1987).
Although the mdx mouse presents some limitations compared to
DMDpatients, due to the fact that skeletalmuscles ofmdxmiceundergo
extensive necrosis only early in neonatal life, it remains an ideal model
for preclinical tests and proof-of-concept studies (Bentzinger et al.,
2014; Bogdanovich et al., 2002; Colussi et al., 2008; Consalvi et al.,
2013; Denti et al., 2006; Grounds et al., 2008; Jiang et al., 2014;al Embryology, Via A. Scarpa, 14,
arò).
. This is an open access article underKainulainen et al., 2015; Minetti et al., 2006; Price et al., 2014; Stupka
et al., 2006; Tedesco et al., 2011; Vidal et al., 2012; Villalta et al., 2011,
2014; von Maltzahn et al., 2012; Willmann et al., 2009). Different ani-
mal models, including the double mutant mice like mdx deficient for
MyoD1, utrophin, parvalbumin, alpha7 integrin, or mTR (telomerase),
have been generated and all of them share many phenotypical hall-
marks with DMD (reviewed inWillmann et al., 2009). However, several
aspects, including the genetic basis of the disease, must be considered
when evaluating the animal models for use in the preclinical testing of
potential new treatment options (Willmann et al., 2009). Thus, the
mdx mouse, lacking a functional dystrophin gene, represents the most
valid pre-clinical model, considering also that the double mutant mice
do not resemble the genetic background of DMD patients and are there-
fore less appropriate to predict therapeutic effects (Willmann et al.,
2009).
There is an acute onset of pathology (increased myofiber necrosis
and elevated blood CK) around 3 weeks of age, in which mdxmice dis-
play muscle weakness similarly to DMD patients (Grounds et al., 2008)
and the mdx muscles appear more susceptible to fatigue in vivo than
control mice, similarly to other dystrophic models (Willmann et al.,
2009).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the extent of chronic inflammatory response has been suggested to be
linked to the severity of dystropathology (Pescatori et al., 2007; Porter
et al., 2002). Depletion of macrophages in the mdx mouse model at
the early, acute peak of muscle pathology produced large reductions
in lesions in the plasmalemma of muscle fibers (Wehling et al., 2001),
showing that muscle macrophages that are present during the acute,
degenerative stage of mdx dystrophy are highly cytolytic, and that
they play a central role in the pathogenesis of muscular dystrophy.
Glucocorticoids, themost powerful anti-inflammatory and immuno-
suppressive agents available, are the only available treatment that al-
lows to slow down disease progression in DMD patients (Horber and
Haymond, 1990). However, it is well known from experience in chronic
inflammatory diseases, not involving muscles, that long-term GC treat-
ment causes muscle atrophy secondary to protein catabolism andmus-
cle proteolysis (Horber and Haymond, 1990). Therefore, the efficacy of
GC treatment in DMD patients is the net benefit of positive effects (sup-
pression of inflammation) and negative effects (muscle catabolism). A
better understanding of the inflammatory process in the dystrophic
muscle and of themediators involvedmight open alternative therapeu-
tic perspectives.
In the present study we have focused our attention on the inflam-
matory cytokine interleukin 6 (IL6), based on the evidence that it is
highly expressed in DMD patients and in mdx mouse model and it
also plays a major role in inducing the transition from an acute neu-
trophilic infiltrate to a chronic type mononuclear cell infiltrate
(Gabay, 2006).
IL6 is a pleiotropic cytokine that can contribute to the positive regu-
lation of muscle homeostasis under physiological conditions and to the
negative regulation of the muscle phenotype under some pathological
circumstances (Fuster and Walsh, 2014; Munoz-Canoves et al., 2013).
The complex actions of IL6 may be linked to the different manners by
which this cytokine signals at the plasma membrane and by the differ-
ent signaling pathways that can activate (Fuster and Walsh, 2014;
Munoz-Canoves et al., 2013; Pedersen and Febbraio, 2008). Based on
the activation of either classic or trans-signaling, IL6 can promotemark-
edly different cellular responses. IL6 trans-signaling, which requires the
soluble IL6R (sIL6R), is pro-inflammatory, whereas classic IL6 signaling,
mediated by membrane-bound receptor, promotes regenerative or
anti-inflammatory activities of the cytokine (Rose-John, 2012).
Circulating IL6 levels are normally very low or undetectable and are
markedly increased in several diseases associated with inflammation,
inducing the transition from an acute to a chronic inflammatory re-
sponse (Gabay, 2006). IL6 is also locally and transiently produced in re-
sponse to exercise and injury, and it plays an important role in satellite
cell proliferation and muscle growth (Kurek et al., 1996; Serrano et al.,
2008). In contrast, increasedmuscle proteolysis was found after admin-
istration of high doses or long-term exposure to IL6 in rodents
(Goodman, 1994; Haddad et al., 2005; Tsujinaka et al., 1995). We
recently demonstrated that treatment of C2C12myogenic cells with re-
combinant IL6 resulted in a dramatic inhibition of myoblast differentia-
tion (Pelosi et al., 2014). Interestingly, the inhibition of IL6 activity in an
injuredmuscle, using ananti-interleukin-6 receptor antibody, promotes
muscle regeneration via immune modulation (Fujita et al., 2014),
whereas the inhibition of the IL6 intracellular mediator, namely the
Jak/Stat pathway, stimulates muscle regeneration in both aged and dys-
trophicmice (Price et al., 2014; Tierney et al., 2014). The opposite effects
exerted by IL6 can be justified considering the concept of hormesis, in
which a low dose of a substance/molecule is stimulatory/homeostatic
and a high dose is inhibitory/catabolic. Moreover, the positive effects
of IL6 are normally associated with its transient production and short-
term action. In contrast, persistent inflammatory conditions, including
muscular dystrophy, are associated with long-lasting elevated systemic
IL6 levels. Thus, muscle tissue might benefit from low and transient in-
creases in IL6, whereas it is damaged by exposure to persistently high
levels of this cytokine (Scott et al., 1996).In the current study, we investigated whether specific blockade of
IL6 activities may represent a potential therapeutic to treat human
DMD. We revealed that blockade of IL6 activity in mdx mice, using a
neutralizing antibody against the IL6 receptor (moAb-Il6r), confers
robustness to dystrophicmuscle, impedes the activation of a chronic in-
flammatory response, significantly reduces necrosis, activates the
circuitry ofmuscle differentiation andmaturation. This results in a func-
tional homeostatic maintenance of dystrophic muscle.
2. Materials and Methods
2.1. Mice
Wild type and mdx mice were maintained according to the institu-
tional guidelines of the animal facility of the unit of Histology andMed-
ical Embryology. Mdx male mice (C57BL10) (purchased from Jackson
Laboratories) were injected subcutaneously, starting at 15 days of age,
with control IgG1 or with the neutralizing monoclonal antibody
MR16-1 (kindly provided by Chugai Pharmaceutical Co., Ltd) (Okazaki
et al., 2002) to the murine Il6 receptor at a dose of 100 μg/g of body
weight and then twice a week with 20 μg/g (for a total of 5 doses) in
PBS. Mice were sacrificed at day 30 of age. All animal experiments
were approved by the ethics committee of Sapienza University of
Rome-Unit of Histology and Medical Embryology and were performed
in accordance with the current version of the Italian Law on the Protec-
tion of Animals.
2.2. Patients
All DMD patients had a molecular genetic detection of a mutation in
the dystrophin gene predicting a marked dystrophin-deficiency. Sera
from 29 non-treated DMD patients, 22 DMD patients treated with
glucocorticoids and from 26 age-matched healthy controls were also
collected. The human studies have been reviewed by the ethics commit-
tee of Bambino Gesù Children's Hospital and have therefore been
performed in accordance with the ethical standards laid down in an ap-
propriate version of the 1964 Declaration of Helsinki. All persons gave
their informed consent prior to their inclusion in the study.
2.3. Treadmill Tests
The treadmill testswere performed using the LE8700 Treadmill Con-
trol (Panlab sl) (Cassano et al., 2008). Four week old mdx and moAb-
Il6r-treated mice were acclimated to treadmill running (5 m/min for
5 min, after which the speed was increased 1 m/min every 2 min up
to 9 m/min) before the test was performed. The mice (minimum 4 ani-
mals/strain) ran on the treadmill at an inclination of 0° at 5 m/min for
5 min, after which the speed was increased 0.6 m/min every 1 min.
The test was stopped when the mouse remained on the shocker plate
for more than 20 s without attempting to re-engage the treadmill, and
the time to exhaustion was determined. The test was repeated four
times (every two days).
2.4. Evans Blue Staining and Confocal Microscopy
Intraperitoneal injection of Evans blue dye (EBD) (100 μl of 1% EBD
per 10 g of body mass) was performed on a minimum of 5 animals/
strain (wild type, moAb-Il6r-treated mdx, and IgG1-treated control
mdx mice). Fluorescent fibers were viewed under an inverted micro-
scope (Axioskop 2 plus; Carl Zeiss Microimaging, Inc.), and images
were processed using Axiovision 3.1 and analyzed using Scion Image
4.0.3.2. software. Confocal microscopy (Leica Laser Scanning TCS SP2)
was used to analyze the total intensity of EBD fluorescence, which rep-
resents the full amount of fluorescence held within the entire z-axis of
the series, and the mean amplitude of fluorescence in mdx and moAb-
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least three separate experiments, were analyzed.2.5. Immunofluorescence Analysis
Frozen human muscle biopsy sections were fixed in ice-cold ace-
tone. Tissue sections were incubated 2 h at 37 °C with a mouse anti-
human antibody against IL6 (R&D Systems, USA). The secondary anti-
body against mouse IgG, fluorescein conjugated (Chemicon, USA) was
applied and incubated for 1 h at room temperature. Sections were also
labeled with a polyclonal rabbit anti-human antibody against nidogen
(Calbiochem) and then with the appropriate secondary antibody la-
beled with Alexa Fluor 555 (Invitrogen, Life Technologies, USA) 1 h at
37 °C.2.6. Protein Extraction, Western Blot Analysis, ELISA, and Antibody Array
Diaphragm muscles from at least 5 animals/strain (wild type, mdx,
and moAb-Il6r-treated and untreated mdx mice) were homogenized
in modified lysis buffer (Tris–HCl, pH 7.5/20 mM, EDTA/2 mM, EGTA/
2 mM, sucrose/250 mM, DTT/5 mM, Triton-X/0.1%, PMSF/1 mM, NaF/
10 mM, SOV4/0.2 mM, cocktail protease inhibitors/1× (Sigma) and
processed for western blot analysis. Filters were blottedwith antibodies
against: pStat3 (Tyr705) (cat #9145, Cell Signaling), Stat3 (cat # 9132,
Cell Signaling); NFkBp65 (ser536) (cat # 3033, Cell Signaling); and
NFkB (cat #4764, Cell Signaling). Signals were captured by ChemiDoc-
It® Imaging System (UVP, LLC) and densitometric analysis was per-
formed with VisionWorks®LS Image Acquisition and Analysis Software
(UVP, LLC). ELISA assay was performed using either a human (to detect
IL6; cat # HS600B) or mouse (to detect Il6, cat # M6000B, and Tnfα, cat
#MTA00B) Quantikine® Colorimetric Sandwich ELISAs (R&D Systems),
according to manufacturer's protocol. Il2 expression was evaluated on
the diaphragm of at least 3 animals/strain and with 2 biological repli-
cates, using a RayBio® Mouse Antibody Array-G series (RayBiotech,
Inc.), according to manufacturer's protocol. The intensities of signals
were quantified with RayBio® Antibody Array Analysis Tool software.2.7. RNA Extraction and Quantitative RT-PCR
Total RNA extraction was performed with tissue lyser (QIAGEN) in
TriRiagentTM (Sigma). To synthesize single-stranded cDNA, 10 ng of
total RNA was reverse transcribed using the TaqMan® MicroRNA Re-
verse Transcription Kit (Applied Biosystem), while double-stranded
cDNA was synthesized with the QuantiTect Reverse Transcription kit
(Qiagen). miRNA and mRNA analyses were performed on an ABI
PRISM 7500 SDS (Applied Biosystems), using specific TaqMan assays
(Applied Biosystems). Relative quantification was performed using en-
dogenous controls U6 snRNA for miRNAs and Hprt1 for mRNAs (Ap-
plied Biosystems, USA). The relative expression was calculated using
the 2−DDCt method.2.8. Statistical Analysis
Statistical analysis was performed with GraphPad Prism Software.
All data, if not differently specified,were expressed asmean±SEM. Dif-
ference among groups were assessed with one-way ANOVA with a
Bonferroni post-test, or Dunn's post-test and between pairs with
Mann–Whitney test or Student's t test assuming two-tailed distribu-
tions. Sample size was predetermined based on the variability observed
in preliminary and similar experiments. All experiments requiring ani-
mal models were subjected to randomization based on litter. Investiga-
tors were not blinded to group allocation or outcome assessment.
p b 0.05 is considered statistically significant.2.8.1. Role of Funding Source
The studywasmainly supported by Telethon (GGP13013) and part-
ly by AFM, PRIN, and ASI. The funders had no involvement in the design,
collection, analysis, interpretation, writing or decision to submit the
article.
3. Results
3.1. IL6 Levels are Significantly Increased in DMD Patients and mdx Mouse
Model
In this study, we tested the effect of therapeutic inhibition of IL6 re-
ceptor (Il6r) to ameliorate the dystrophic phenotype in young (4weeks
of age)mdxmice, based on the evidence that IL6 protein expressionwas
detected in infiltrating cells in the interstitial space amongmuscle fibers
of DMD patients (Fig. 1A) andwas significantly up-regulated in the dia-
phragm muscle of dystrophic mdx mice (Fig. 1B). The up-regulation of
Il6 in themuscle ofmdxmicewas also associatedwith the increased ex-
pression of phosphorylated/active form of Stat3 (Fig. 1C), a molecular
target of activated Il6 signaling (Heinrich et al., 1998). Moreover, circu-
lating IL6 levelswere significantly increased in DMD patients before ini-
tiation of treatment with glucocorticoids (GCs), compared to age
matched controls and to DMD patients who were receiving GC treat-
ment (Fig. 1D).
These data suggest that elevated levels of IL6 in DMD patients and in
mdx dystrophic mouse model might contribute to exacerbate the dys-
trophic phenotype, sustaining an inflammatory response. Thus, it is con-
ceivable to hypothesize that a blockade of IL6 signaling represents an
approach for treatment of DMD. We therefore tested the hypothesis
that the inhibition of Il6 effects in themdxmice, using a neutralizing an-
tibody against the Il6 receptor (moAb-Il6r) would lead to an ameliora-
tion of the muscle and functional phenotype.
3.2. Inhibition of Il6 Activity Counteracts Necrosis and Improves Functional
Performance of Dystrophic Muscles
In order to investigate a possible therapeutic approach based on Il6
antagonism, we verified whether neutralization of Il6 activity amelio-
rated the dystrophic phenotype. Mdx mice were treated at 15 days of
age with a neutralizing monoclonal antibody to the Il6 receptor
(moAb-Il6r-treated), or IgG alone (control IgG-treated) (Fig. 2A). Mice
were sacrificed at 4 weeks of age, at the stage when the acute manifes-
tations of the disease in the mdx mouse model are clearly evident
(Grounds et al., 2008).
We investigated the integrity of sarcolemma, measured by the per-
centage of necrosis, analyzing Evans blue dye (EBD) uptake in whole
mount diaphragm muscles. We observed a marked reduction of EBD
uptake inmoAb-Il6r-treatedmdxmice compared to untreated and con-
trol IgG-treated mdx mice (Fig. 2B and C).
It is known that dystrophic muscle is sensitive to mechanical stress,
increasing myofiber necrosis and decreasing muscle strength (Brussee
et al., 1997; De Luca et al., 2003; Okano et al., 2005). Treadmill running
has been used to exacerbate the disease and to measure improvements
of therapeutic approaches inmdxmice (Grounds et al., 2008). Although
the treadmill test does not provide a direct evidence about muscle
strength, it is a useful experimental tool to analyze the capability of dys-
trophic muscle to respond to mechanical damage induced by exercise
(Burdi et al., 2006; Pierno et al., 2007). In fact, treadmill increases mus-
cle necrosis in mdx mice, exacerbating the disease. Moreover, the
in vivo weakness produced by such a protocol is observed exclusively
in mdx mice with no similar effects in wild type mice; thus providing
a reliable in vivo index with which to rapidly monitor potential drug ef-
ficacy (De Luca et al., 2002, 2003; Granchelli et al., 2000). In fact, the
ability of mdx mice to run on a treadmill (measured as distance run/
day or week, or the time taken to cover a particular distance) is an indi-
cation of their general well-being and muscle function (Cassano et al.,
Fig. 1. IL6 levels are accumulated in DMD patients and mdx mouse model. (A) Immunofluorescence staining of healthy human (left panel) and DMD (right panel) muscle biopsies
immunolabeled with a rabbit anti-human nidogen (red) together with a mouse anti human IL6 (green). Images are representative of 29 experiments. Scale bar, 50 μm. (B) Expression
of Il6 was evaluated by real time PCR in diaphragms of indicated genotypes at 4 weeks of age. Values represent mean ± SEM; n = 5. p value by Mann–Whitney test. (C) Western blot
analysis (right panel shows a representative image) for active phospho-Stat3 (Tyr705) and total Stat3 protein performed on diaphragm muscles of wild type (WT) and mdx mice of
4weeks of age. Values representmean± SEM; n=6 to 9 per group. p value byMann–Whitney test. (D) IL6 serum levels in healthy controls, untreatedDMDpatients and inDMDpatients
treated with corticosteroids. Values represent medians. n = 22 to 26 per group; NS = not significant. *p = 0.005; **p = 0.0001 by Mann–Whitney Rank Sum test.
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young mdx mice at the acute phase of dystropathology show muscle
weakness and the mdx muscles appear more susceptible to fatigue
in vivo than control mice (Grounds et al., 2008).
A treadmill test was performed in order to evaluate the effect of the
inhibition of Il6 activities on muscle performance of dystrophic mice
(Fig. 2D). This in vivo motility assay revealed that moAb-Il6r-treated
mdx mice performed much better than untreated littermates, covering
on average a longer distance in comparison to their untreated counter-
parts (Fig. 2D). Of note, the mdx untreated mice were exhausted after
the trained session and remained prostrated in the cages for an extend-
ed period of time compared to moAb-Il6r-treated mdx littermates. Im-
portantly, following treadmill exercise we observed significantly less
muscle damage, evaluated by EBD uptake, in moAb-Il6r-treated mice
in comparison to aged-matched untreated mdx mice (Fig. 2E). These
data suggest that moAb-Il6r-treated mdx mice were more resistant to
damage and displayed an increased muscular performance.
3.3. Inhibition of Il6 Effects Reduces the Inflammatory Response in Dystro-
phic Muscle
In order to evaluate whether reduced necrosis and exercise-induced
damage in moAb-Il6r-treated mdx diaphragm were associated with
changes in muscle inflammation, we analyzed the expression markers
of the inflammatory response in moAb-Il6r-treated and untreated
mdx mice. Interestingly, Il6 blockade resulted in a significant decrease
in the synthesis and phosphorylation of NFkB protein (Fig. 3A) and in
a marked down-modulation of Tnfα (Fig. 3B) expression. We also eval-
uated the expression of markers of the anti-inflammatory response
(Tidball and Villalta, 2010; Villalta et al., 2011). We found an up-
regulation of Il1rn (Fig. 3C), Slpi (Fig. 3D) and Il10 (Fig. 3E) in moAb-
Il6r-treated mdx compared to untreated mdx mice.
One of the more interesting recent discoveries in DMD is that infil-
trating regulatory T cells (Tregs) suppress muscle inflammation and
muscle injury in this disease (Villalta et al., 2014). To evaluate the pos-
sibility that blocking Il6 alters T cell activity in dystrophic muscles, we
analyzed relevant markers of Tregs, including Foxp3 expression
(Fig. 3F). We did not observe any significant modulation in Foxp3expression between moAb-Il6r-treated and untreated mdx mice
(Fig. 3F). Nevertheless, we observed that Mir155, a positive regulator
of Treg cell differentiation and homeostasis (Curtale et al., 2013;
Kohlhaas et al., 2009; Lu et al., 2009), was strongly up regulated in
moAb-Il6r-treated compared to untreated mdx mice (Fig. 3G). More-
over, we revealed a significant down regulation of the cytokine Il2, a
strong modulator of Treg cells, in the diaphragm of moAb-Il6r-treated
mdx mice compared to untreated mdx littermates (Fig. 3H), further
supporting the evidence that blockade of Il6 interferes with the estab-
lishment of a chronic inflammatory response.
3.4. Il6 Blockade Improves the Homeostatic Maintenance of Dystrophic
Muscle
The reduced necrosis and inflammation suggest a stabilization of
dystrophic muscle phenotype with a reduced cyclic progression of ne-
crosis and regeneration. These evidences were further supported by
the analysis of relevant markers of activated, proliferating and differen-
tiating satellite cells (Musaro, 2014; Rantanen et al., 1995). We found
that Pax7 expression did not significantly change between untreated
and moAb-Il6r-treated mdx mice (Fig. 4A), whereas MyoD1 expression
was significantly up-regulated in moAb-Il6r-treated mdx compared to
untreated mdxmice (Fig. 4B), suggesting that satellite cells are induced
to differentiate. In fact, we observed a significant down regulation of des-
min (Fig. 4C), a marker of proliferating satellite cells (Musaro, 2014;
Rantanen et al., 1995), and a significant up-regulation of myogenin
(Fig. 4D), a critical player for the terminal differentiation of myoblasts
(Hasty et al., 1993; Musaro, 2014; Nabeshima et al., 1993). It has been
demonstrated that Il4 acts as amyoblast recruitment factor duringmam-
malianmuscle differentiation and growth (Horsley et al., 2003). Real time
PCR analysis revealed a significant up-regulation of Il4 expression in the
muscle of moAb-Il6r-treated mdx compared to untreated mdx mice
(Fig. 4E), suggesting that Il6r neutralization leads to changes in the dys-
trophic muscle environment, favoring anti-inflammatory responses and
improvement in muscle repair.
To better define the improvement in the stabilization ofmuscle phe-
notype and muscle growth in anti-Il6r treated mice, we analyzed other
relevant markers of muscle differentiation.
Fig. 2. Il6 blockade confers on dystrophic mdxmuscle resistance to degeneration and ameliorate dystrophic phenotype. (A) Schematic representation of moAb-Il6r treatment protocol in
15-week-oldmdxmice.MoAb-Il6rwas administered at an initial dose of 100 μg/g of bodyweight and thenmdxmicewere treated twice aweekwith 20 μg/g (for a total of 5 doses) in PBS.
Mice were sacrificed at day 30 of age. (B) Representative images of whole diaphragm, stained with Evans blue dye (EBD), frommoAb-Il6r treated and untreated mdxmice of 4 weeks of
age. Necrotic region is blue in visiblemicroscopy (toppanels) and red influorescencemicroscopy (bottompanel). Scale bar, 500 μm. (C) Confocalmicroscopy: representative images of one
spatial series (from 0 to 80 μm) composed of 8 optical sectionswith a step size of 10 μm, fromwhole diaphragms of 4-week-oldmdx andmoAb-Il6r-treatedmdxmice. EBD ismore diffuse
in the diaphragm ofmdxmice (a–h) than the diaphragm of moAb-Il6r-treatedmdxmice (i–r). Scale bar, 150 μm. Graphs showing quantification of EBD uptake. Values representmean±
SEM; n= 5 to 9 per group. p values, using oneway ANOVA.ND, no detected. (D) Exhaustion treadmill tests carried onwild-type (WT), untreated, andmoAb-Il6r-treatedmdxmice. Note
that moAb-Il6r-treatedmdx showed increased running performance compared to untreatedmdxmice. Muscle strength of treated and control animals was measured as time (top histo-
gram) or distance to exhaustion (bottom histogram). Values represent mean ± SEM; n = 4 per group. *p b 0.05, ***p b 0.0005, #p b 0.05, and ###p b 0.0005 using one way ANOVA.
(E) Representative images of confocal analysis (top panels) and quantification of EBD uptake (bottom panels) performed on 240 optical sections fromwhole diaphragmmuscles of indi-
cated genotypes. Scale bar, 150 μm. Necrotic fibers evaluated by total intensity and mean amplitude of fluorescence (bottom) are significantly reduced in moAb-Il6r exercised mdxmice
compared to mdx exercised mice. Values represent mean ± SEM; n = 5 to 9 per group. **p b 0.005, *p b 0.05, ###p b 0.0005, and ##p b 0.005 using one way ANOVA.
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(Fig. 4F), a muscle specific miRNA activated by MyoD1, in moAb-Il6r-
treated mdx compared to untreated mdxmice. Through Mir206 activa-
tion, MyoD1 might facilitate progression toward terminal differentia-
tion (Chen et al., 2010; Hirai et al., 2010). Other key players that
function during muscle regeneration, differentiation and homeostaticmaintenance of skeletal muscle tissues are the non-muscle-specific
Mir24, Mir34c, Mir335, and Mir214 (Eisenberg et al., 2009; Erriquez
et al., 2013; Greco et al., 2009; Sun et al., 2008). We observed that
Mir24, Mir34c, Mir335, and Mir214 were significantly up-regulated in
the diaphragm of moAb-Il6r-treated mdx mice compared to untreated
mdx littermates (Fig. 4G–M).
Fig. 3. Il6 blockademodulates the inflammatory response. (A) Expression of NFkB (NFkB p65) active and total (NFkB TOT) proteins was evaluated bywestern immunoblotting (left panel
shows a representative image) in the diaphragmofwild type (WT),moAb-Il6r-treated, and untreatedmdxmice at 4weeks (4W) of age. Immunoblotting for Gapdh served as a control for
protein loading. Graph shows quantification by densitometric analysis (right panel). Values represent medians. n = 7 to 9 per group. p value using Mann–Whitney Rank Sum test. In the
left panel the laneswere run on the same gel butwere non contiguous. (B) ELISA assay to evaluate the concentration (pg permg ofmuscular protein) of Tnfα in the diaphragmof indicated
genotypes at 4 weeks of age (4W). Values representmean± SEM; n= 5 to 6 per group. **p b 0.005 and #p b 0.05 using one way ANOVA. (C–G) Expression of Il1rn (C), Slpi (D), Il10 (E),
Foxp3 (F), and Mir155 (G) was evaluated by real time PCR in diaphragms of indicated genotypes at 4 weeks (4W) of age. Of note, Slpi expression was undetectable in the diaphragm of
both 4-week-old WT and mdx mice, whereas Foxp3 expression was undetectable in the diaphragm of 4-week-old WT mice. Values represent mean ± SEM; n = 4 to 12 per group.
*p b 0.05, #p b 0.05, and ##p b 0.005 using one way ANOVA. ND, no detected. (H) Il2 expression, evaluated by RayBio®Mouse Antibody Array-G series (RayBiotech, Inc.), in diaphragms
of wild type (WT), untreated mdx and moAb-Il6r-treated mdx mice at 4 weeks (4 W) of age. Values represent mean ± SEM; n = 3 to 4 per group. p value using t-test.
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visions by acting through the planar cell polarity pathway (Le et al.,
2009). Specifically, Wnt7a, which is upregulated late in regeneration,
promotes the symmetric expansion of satellite stem cells to replenish
the stem cell pool and maintain a homeostatic level of stem cells
through rounds of regeneration (Le et al., 2009). It has been also report-
ed thatWnt7a treatment amelioratesmuscular dystrophy, reducing the
level of contractile damage and significantly increasingmuscle strength
of mdx mice (von Maltzahn et al., 2012).
Interestingly, we found an up-regulation ofWnt7a in the diaphragm
of moAb-Il6r-treated mdx mice, compared with untreated mdx litter-
mates (Fig. 4M).
These data suggest that the modulation of Il6 activities ameliorates
muscle diseases in a dystrophic mouse model, without altering the in-
duction of factors associated with muscle differentiation and growth.
To further reveal whether blockade of Il6 activity interferes with the
myogenic program we treated C2C12, a muscle cell line derived from
adult mouse satellite cells (Blau et al., 1985; Yaffe and Saxel, 1977),
with Il6r-neutralizing antibody and we did not observe any significantalteration in the myogenic properties, including muscle proliferation
and differentiation (data not shown).
4. Discussion
Themajor findings of this study indicate that inhibition of Il6 activity
is a possible therapeutic strategy to counteract necrosis and the conse-
quences of chronic inflammation in muscular dystrophy.
We found that Il6 is highly expressed in the plasma andmuscle from
patients with DMD and from youngmdxmice. Thus, it is conceivable to
hypothesize that a blockade of Il6 signaling represents an approach for
treatment of DMD. We therefore tested the hypothesis that the inhibi-
tion of Il6 effects in the mdxmice, using a neutralizing antibody against
the Il6 receptor (moAb-Il6r) would lead to an amelioration of the mus-
cle and functional phenotype. Mdxmice at the pre-necrotic stage of the
disease (i.e. 2 weeks of age) were treated and sacrificed at 4 weeks of
age, which represents the stage when marked degeneration and regen-
eration ofmuscle fibers are observed. The choice to interferewith Il6 ac-
tivity at the pre-necrotic stage of the disease in mdxmice was based on
Fig. 4. Il6 blockade improves the homeostatic maintenance of dystrophic muscle. (A–M) Expression of Pax7 (A), MyoD1 (B), desmin (C), myogenin (D), Il4 (E), Mir206 (F), Mir24 (G),
Mir34c (H), Mir335 (I), Mir214 (L), and Wnt7a (M) was evaluated by real time PCR in diaphragms of wild type (WT), untreated mdx and moAb-Il6r-treated mdx mice at 4 weeks
(4 W) of age. Values represent mean ± SEM; n = 4 to 6 per group. *p b 0.05, **p b 0.005, ***p b 0.0005, #p b 0.05, ##p b 0.005, and ###p b 0.0005 using one way ANOVA.
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ic damage to mdxmuscles occurs, b) analysis and interpretation of data
are simplified due to the absence of pre-existing background tissue
damage, and c) this young age relates to childhood events in human
DMD, therefore making this approach more easily translatable to pa-
tients (Grounds et al., 2008).
Interestingly, the acute onset of myofiber necrosis provides a good
model to study therapeutic interventions designed to prevent or reduce
necrosis, since a reduction in dystropathology is easily identified
(Grounds and Torrisi, 2004; Radley and Grounds, 2006; Shavlakadze
et al., 2004; Stupka et al. 2001).
Our results demonstrate that inhibition of Il6 activities is beneficial
to dystrophic muscle decreasing inflammation-induced myonecrosis,
favoring the maintenance of muscle function, and preventing exercise-
induced fiber damage and loss of muscle strength. These findings
were paralleled by inhibition of NFkB expression and with modulation
of the inflammatory response, including down-regulation of Tnfα and
Il2 and upregulation of the anti-inflammatory mediators Il10 and Slpi.
It has been demonstrated that treated mdx mice with Il2/anti-Il2
complexes showed an increase in Il10 concentrations and suppression
of type 1 inflammation (Villalta et al., 2014). Thus, our data demonstrat-
ed that blockade Il6 resulted in a significant decrease in the expression
and activity of important mediators of the type 1 inflammatory re-
sponse, associated with up-regulation of relevant markers of the anti-inflammatory response. This results in the establishment of a qualitative
environment that might guarantee the homeostatic maintenance of
muscle phenotype and therefore the delay in the progression of muscu-
lar dystrophy.
The improvement in the stabilization of muscle phenotype in anti-
Il6r treated mdx mice was monitored analyzing relevant markers of
muscle differentiation and maturation. Interestingly, we observed an
up-regulation of factors that favor muscle differentiation and matura-
tion, including myoD1, myogenin, Il4, Mir24, Mir206, Mir34c, Mir335,
and Mir214. Interestingly, in addition to being strongly induced during
myogenesis, Mir24 expression ismaintained at high levels in terminally
differentiated muscle tissues (Sun et al., 2008). Moreover, Mir34c and
Mir335, alongwithMir206, are up-regulated followingmyoblast differ-
entiation in vitro (Greco et al., 2009), whereas Mir214 promotes cell
cycle exit and skeletal muscle differentiation (Juan et al., 2009; Liu
et al., 2010).
All of these data suggest that the maturation of the myogenic pro-
gram and the homeostatic maintenance of dystrophic muscle tissues,
which are severely affected by the absence of dystrophin expression,
are facilitated by interfering with the pathologic activity of Il6.
Our results, conversely to those recently reported (Kostek et al.,
2012), demonstrated that the methodologies employed, and the dose
regimen of Il6r neutralizing antibody that has been used provide the
rational for therapeutic approaches in human DMD based on IL6
292 L. Pelosi et al. / EBioMedicine 2 (2015) 285–293inhibitors. Basically, several differences in themethodologies employed,
including dosing regimen, and in the analysis and outcomes examined
are present between the two studies. Although improvements were
observed in the Kostek et al. study (Grounds and Torrisi, 2004), most
of them did not reach statistical significance. Despite this, interestingly,
and in agreement with molecular results of our study they found in-
creased levels of Il10 in anti-Il6r treated mdx mice. This piece of data
is in evident contradictionwith their conclusion that inflammation is in-
creased. It is reasonable to speculate that by inhibiting Il6, we reduced
the inflammatory response in dystrophic mice and created a qualitative
environment that makes the dystrophic muscle more resistant to the
damage exerted by mechanical contraction.
Moreover, the recent reports indicating that inhibition of Stat3
activity, a downstream effector of Il6, enhances muscle repair and
functional performance (Price et al., 2014; Tierney et al., 2014)
strengthens our data and conclusion, considering that approaches
based on the specific targeting of one inflammatory mediator may be
more specific, more efficacious, and with fewer side effects, compared
to glucocorticoids, as it is the case in chronic inflammatory diseases.
In conclusion, our work is consistent with a model in which moAb-
Il6r-treatment confers robustness to dystrophic muscle, significantly
reduces necrosis, impedes the activation of a chronic inflammatory
response, activates the circuitry of muscle differentiation andmaturation,
guaranteeing a functional homeostatic maintenance of dystrophic
muscle.
This might result in reduction in the cycle of regeneration and de-
generation, which characterize the dystrophic untreated muscle, and
therefore the need to continuously activate satellite cells. Duchenne
muscular dystrophy is a disease of accelerated damage to muscle that
causes the muscle stem cells (satellite cells) to eventually be used up.
Thus, only treatments that stabilize the muscle so that continuous
satellite cell repair is not needed will delay the progression of disease.
Much of the damage comes from inflammatory response. Indeed, in
the face of continuous inflammation, the satellite cells cannot properly
repair themuscle andmay even contribute to worsening of the disease.
The information derived by this study will have an impact on the
immediate translation of IL6 blockade in the pharmacological treatment
of DMD patients, since IL6 inhibitors are already available and their use
havebeen recently approved in childrenwith systemic juvenile idiopathic
arthritis based on a favorable benefit/risk ratio (De Benedetti et al., 2012).
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